Senescence-Associated Secretory Phenotype (SASP) in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders. [1]
Cellular senescence is a state of irreversible cell cycle arrest that emerges in response to various stresses, including telomere erosion, DNA damage, oncogene activation, and mitochondrial dysfunction 1. While senescence serves as a tumor suppression mechanism, the accumulation of senescent cells over time contributes to tissue dysfunction through the senescence-associated secretory phenotype (SASP), a complex secretome that includes pro-inflammatory cytokines, chemokines, growth factors, proteases, and bioactive lipids 2. In the aging brain, SASP drives chronic neuroinflammation, disrupts neuronal function, and accelerates neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) 3. [2]
The primary driver of SASP is the persistent DNA damage response (DDR). When cells experience telomere shortening or genotoxic stress, ATM/ATR kinases phosphorylate downstream effectors including p53, CHK1, and CHK2, leading to cell cycle arrest 4. In neurons and glia, chronic DDR activation—without complete repair—triggers SASP: [3]
Mitochondrial dysfunction is both a cause and consequence of cellular senescence. Damaged mitochondria produce excess reactive oxygen species (ROS), causing oxidative damage to nuclear and mitochondrial DNA 8. Key connections include: [4]
The cGAS-STING cytosolic DNA sensing pathway is a critical activator of SASP in senescent cells. When DNA accumulates in the cytosol (from nuclear envelope breakdown, mitochondrial DNA release, or foreign DNA), cGAS catalyzes cGAMP production, which activates STING and downstream TBK1-IRF3 signaling 12. This pathway: [5]
| Cytokine | Function | Neurodegenerative Relevance | [6]
|----------|----------|----------------------------| [7]
| IL-1β | Pro-inflammatory, activates microglia | Drives chronic neuroinflammation in AD 13 | [8]
| IL-6 | Acute phase response, B cell maturation | Elevated in AD/PD CSF 14 | [9]
| IL-8 | Chemoattractant for neutrophils | Attracts peripheral immune cells to brain 15 | [10]
| TNF-α | Master inflammatory regulator | Synaptic dysfunction in AD 16 | [11]
Surprisingly, post-mitotic neurons can enter a senescent-like state characterized by: [12]
Microglia adopt SASP in the aging brain, contributing to chronic neuroinflammation: [13]
Aβ and SASP create a vicious cycle: [14]
The substantia nigra pars compacta (SNc) dopaminergic neurons are particularly vulnerable to senescence: [15]
Astrocytes and microglia in PD brain show SASP-like states: [16]
| Drug | Target | Status | [17]
|------|--------|--------| [18]
| Dasatinib + Quercetin | Pan-tyrosine kinase + senolytic | Clinical trials 35 | [19]
| Navitoclax (ABT-263) | Bcl-2 family | Preclinical 36 | [20]
| Fisetin | mTOR, senolytic | Preclinical 37 | [21]
| Metformin | AMPK, reduces SASP | Clinical trials 38 | [22]
SASP represents a critical link between aging, cellular senescence, and neurodegenerative disease. The chronic inflammatory state induced by SASP creates a permissive environment for protein aggregation, synaptic dysfunction, and neuronal death. Therapeutic strategies targeting senescent cells or SASP components offer promising avenues for disease modification. [23]
Additional evidence sources: [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37]
Wiley et al. Mitokines and aging (2016). 2016. ↩︎
Dou et al. cGAS-STING and senescence (2017). 2017. ↩︎
Griffin et al. IL-1 in AD (2001). 2001. ↩︎
Glaser et al. IL-6 in neurodegeneration (2003). 2003. ↩︎
McAlpine et al. TNF and synapses (2011). 2011. ↩︎
Ishizuka et al. CCL2 in AD (2008). 2008. ↩︎
Semple et al. Chemokines in neuroinflammation (2010). 2010. ↩︎
Tran et al. CXCL12 in neurogenesis (2008). 2008. ↩︎
Flanders and Burmester, TGF-β in neurodegeneration (2003). 2003. ↩︎
Tarkowski et al. VEGF in AD (2006). 2006. ↩︎
Lee et al. MMPs in AD (2003). 2003. ↩︎
Bohren et al. PAI-1 and aging (2004). 2004. ↩︎
Jurk et al. Neuronal senescence (2012). 2012. ↩︎
Mohammad et al. Tau and senescence (2015). 2015. ↩︎
Wiley et al. Mitochondrial senescence (2015). 2015. ↩︎
Heneka et al. NLRP3 in AD (2015). 2015. ↩︎
Stevens et al. Complement and synapses (2015). 2015. ↩︎
Ulrich et al. TREM2 and microglia (2016). 2016. ↩︎
Ryan et al. SNc vulnerability (2013). 2013. ↩︎
Zecca et al. Neuromelanin and aging (2008). 2008. ↩︎
Schiapparelli et al. α-synuclein and DNA damage (2015). 2015. ↩︎
Lee et al. Astrocyte SASP and α-synuclein (2014). 2014. ↩︎
Chang et al. Navitoclax senolytic (2016). 2016. ↩︎
Yousefzadeh et al. Fisetin senolytic (2018). 2018. ↩︎
Barzilai et al. Metformin and aging (2016). 2016. ↩︎
Laberge et al. mTOR and SASP (2012). 2012. ↩︎
Xu et al. JAK inhibitors and SASP (2015). 2015. ↩︎
Freund et al. NF-κB and SASP (2011). 2011. ↩︎
Kale et al. Aspirin and SASP (2014). 2014. ↩︎
Weaver et al. Peripheral IL-6 (2002). 2002. ↩︎
Zhang et al. CXCL12 and cognitive decline (2013). 2013. ↩︎
O'Caoimh et al. PAI-1 and dementia (2016). 2016. ↩︎
Tarkowski et al. CSF IL-1β in AD (2001). 2001. ↩︎
Mogi et al. TGF-β in PD CSF (2009). 2009. ↩︎